Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.57 |
| ▸ | BCR | P11274 | 6/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2939690 | 0.93 | ABL1 (0.60) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945044 | 0.92 | ABL1 (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2938799 | 0.88 | ABL1 (0.60) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945981 | 0.85 | BRAF (0.68) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2941288 | 0.83 | ABL1 (0.68) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2944323 | 0.81 | ABL1 (0.66) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945911 | 0.81 | ABL1 (0.68) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945171 | 0.79 | ABL1 (0.63) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945813 | 0.79 | ABL1 (0.58) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1653882 | 0.78 | ABL1 (0.70) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | claimed |
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | ABL1 72/4885PDGFRA 881/4885BCR 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.